Optio attends Huntington’s Disease Society of America 37th annual convention – Atlanta, June 2022

Optio further reinforces its expertise in neurodegenerative and rare diseases – Eric Miller and Deborah Neville attend the 37th annual HDSA convention held on June 8-10 in Atlanta, GA.  Most Optio Partners have 10+ years of strategic pharmaceutical market planning and global pharmaceutical market development experience in the Huntington’s disease therapeutic arena. Eric Miller, the President of Optio, has 15 consecutive years of involvement in the HD therapeutic area. Optio has consistently advanced the commercial understanding of the HD market by providing actionable insights from a patient, caregiver, clinician and thought leader perspective through market research projects for a variety of pharmaceutical companies.